Applied StemCell provides industry and academic researchers with the ability to leverage the power of induced pluripotent stem cells (iPSC) technology.
Headquartered in Milpitas, California. Applied StemCell Inc. (ASC) is a fast growing biotechnology company headquartered in Milpitas, California.
12/09/2025
Join Kaytrina and Simon in Boston!
Our ASC team will be at ISSCR’s PSC-Derived Therapies Symposium from December 11 to December 12. Harness this great opportunity to meet with our team and learn about how you can fuel your discovery with the power of iPSCs.
Our iPSC reprogramming, gene editing, and differentiation services combined with our deep scientific expertise, proprietary processes, and regulatory insight are designed to support your success.
We’re here as your partner in all your iPSC endeavors.
Join us at Antibody Engineering & Therapeutics 2025 in San Deigo to explore how TARGATT™ large knock-in technology can accelerate your antibody discovery and development.
Our genome engineering platform enables the construction of large libraries directly in mammalian cells, delivering consistent protein expression for pool-based screening. Achieve more relevant data, greater confidence, and faster results—without relying on bacterial or yeast display systems.
Let’s connect. Visit us at Booth 608 or schedule a meeting with our team through the partnering app.
Safe travels, we’ll see you in San Diego!
12/02/2025
Simplify large DNA insertions into mammalian cells.
With pre-engineered cells equipped with our TARGATT™ large knock-in technology, our kits streamline site-specific, multiprotein insertions into the mammalian H11 safe harbor site so you can achieve efficient and reliable expression.
Our TARGATT™ kits:
• Accelerate allogeneic cell therapy development with the ability to knock-in immune evasion components, therapeutic payloads, and logic gates all in a single reaction
• Speed cell line engineering for expression of difficult proteins and multi-protein constructs
• Enable tight stoichiometric control of multi-protein constructs
• And more!
What will it take to bring iPSC-based therapies to the bedside?
Allogeneic approaches are the most promising way for the drug discovery industry to build scalable and cost-effective cell therapies, but donor cell rejection remains an ongoing challenge.
Join Simon Wu, Ph.D., at ISSCR’s PSC-Derived Therapies Symposium to learn more about Applied StemCell’s approaches to building a hypoimmunogenic cell line and how TARGATT™ technology streamlines safer development.
Eliminating the need for lengthy clonal purification workflows, TARGATT™ large knock-in technology delivers consistent expression from cell to cell—accelerating mammalian cell line development and reducing downstream variability.
The key is safe, efficient insertion into the TARGATT™ safe harbor site.
Demonstrated for payloads up to 50 kb, TARGATT™ technology enables multi-cassette gene expression for advanced therapeutic development and more.
Keep your edits on target with TARGATT™ large knock-in technology. Unlike approaches where naked double-strand breaks can lead to off-target events, site-specific TARGATT™ technology keeps your DNA covered for safer genome engineering.
See how TARGATT™ technology efficiently and safely inserts up to 50 kb into the mammalian H11 safe harbor site by visiting https://hubs.ly/Q03TWJgM0
11/11/2025
What would you cure with a 50 kb knock-in?
We’ve successfully knocked in a 50 kilobase multifunctional DNA insert into human induced pluripotent stem cells (iPSCs) using our proprietary TARGATT™ technology.
This milestone represents a significant advance in the size of DNA researchers can safely insert site-specifically into the human genome and get reliable expression from one or more expression cassettes. We’re excited to use this capability to empower cell therapy developers and accelerate the next generation of advanced therapies.
Our collaboration with Ansa Biotechnologies made this possible; their enzymatic DNA synthesis platform was used to construct the 50 kilobase fragment for this insertion. A huge thank you to the Ansa team for their support and innovation!
What if you could simplify large DNA insertions into mammalian cells — with negligible off-target events?
See it in action by trying a kit in your own lab.
Our TARGATT™ large knock-in technology lets you simplify site-specific, multi-protein insertions into the mammalian H11 safe harbor site — delivering efficient, reliable expression every time.
Whether you’re developing allogeneic cell therapies or engineering complex protein constructs, TARGATT™ technology helps you move faster, with precision built in. See the difference. Ask us about our kits:
If you’re attending ARM’s upcoming workshop on the Evolution of the CGT Sector, we hope you can join the panel discussion moderated by our Chief Scientific Officer, Ruby Tsai, Ph.D.
Unable to make it to Washington, DC? There’s a virtual option as well!
The panel “Scale-Up: Advancing allogeneic cell and gene therapy products” will take place on November 5, from 4:00 – 4:45 pm.
Show off your costumes a day early in San Diego! 🎃🦇
Our Senior Business Development Manager, Heather Lundie, will be at BVS’s Community Halloween Party & Vendor Expo tomorrow. Come show off your Halloween costume, enjoy complimentary food and drinks, and learn how our TARGATT™ large knock-in technology can accelerate your cell line development while ensuring safety and reliable expression. No random integrations, no tricks. Just treats.
We hate naked double-stranded DNA just as much as your cells do. 😠
That’s why we provide the platform to keep your cells safe. TARGATT™ large knock-in technology has your DNA covered, ensuring no double-stranded breaks are left naked during genome engineering, eliminating off-target events.
Learn more about moving faster and safer with TARGATT™ technology: https://bit.ly/47vVCQW
10/09/2025
Join our Chief Scientific Officer, Ruby Tsai, Ph.D., and learn how we can Unlock Allogeneic Cell Therapy.
While autologous cell therapies have provided new options for cancer patients, the approach is logistically complex, expensive, and not scalable.
Hear what Ruby Tsai, Ph.D., has to say about how allogeneic cell therapy developers are addressing this durability roadblock, as well as how genome engineering and induced pluripotent stem cells (iPSCs) are making scalable allogeneic cell therapies possible.
The webinar “Unlocking Allogeneic Cell Therapy: Exploring Durable Approaches” will take place on Wednesday, October 22, at 8 am PT / 11 am ET.
Be the first to know and let us send you an email when Applied StemCell, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Applied StemCell Inc. (ASC) is a fast growing biotechnology company headquartered in Milpitas, California. Our goal is to advance gene-editing and stem cell innovationfor biomedical research and the biotechnology industry. After years of research and development, ASC is proud to offer an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications.
We are currently focusing on three areas:
Cell line generation for bio-production and bioassays
Patient-relevant cell models for personalized medicine and
Physiologically predictive animal models of human diseases
We are striving to improve and expand our technologies and product lines to meet the increasing requirements of the biomedical community.
Establishing disease-specific isogenic models
Developing master cell lines for antibody/protein production
Generating iPSCs from patients containing the corrected mutations or inserted genes for pre-clinical applications
Generating animal models (mouse/rat models)
Using our TARGATT™ technology, a gene-of-interest can be specifically inserted at a well-characterized, transcriptionally active locus in the genome with guaranteed transgene expression.
This site-specific Knock-in technology has been first established in mouse models, and we have successfully applied it to human cell lines.
We are moving forward to various projects that will combine the CRISPR/Cas9 technology and TARGATT™ for highly specified transgene expression.
